Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLL001 for the Treatment of ALS
NCT06513546Phase 2Not yet recruiting
- Sponsor
- PLL Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Peptides, Small Molecules
01
Overview
A Phase 2 trial of PLL001 in amyotrophic lateral sclerosis (ALS), sponsored by PLL Therapeutics. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
PLL001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06513546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513546.